Dementia Researcher Vodcast

Extended reality is starting to find a real place in dementia research and care. In this episode, host Dr Byron Creese is joined by David de Jong-Bambagioni, Dr Emilie Brotherhood, and Alice Rowe to explore how virtual, augmented, and mixed reality tools are being used in practice.
Together, they discuss how XR is helping to standardise cognitive assessments, simulate clinical environments, and support earlier and more accurate diagnosis. The conversation also looks at how immersive tools are being used to build empathy, giving clinicians and carers a better sense of what it might feel like to live with dementia.
The panel share examples from their own work, including virtual simulations to distinguish delirium from dementia, and digital environments designed to capture subtle behavioural changes in conditions like frontotemporal dementia. These approaches are opening up new ways to study cognition, behaviour, and patient experience in more realistic and scalable settings.
Alongside the opportunities, the discussion also addresses the challenges. From safeguarding wellbeing to avoiding bias in digital tools, the group reflects on what responsible use looks like, and why co design and inclusive development matter.
This episode offers a practical look at where XR is already making a difference, and where it might go next.
In this episode:
How XR is being used in dementia research and care
Using immersive environments for assessment and empathy
Why co design and lived experience matter
Virtual, augmented, and mixed reality explained simply
Ethical risks and safeguards in vulnerable groups
How researchers are moving into digital health
Getting started with XR and finding collaborators
Inclusion, global perspectives, and reducing bias

A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk.
If you prefer to watch rather than listen, you will find a video version of this podcast on YouTube, on our website, and in selected podcast platforms.
Follow us on social media:
https://www.instagram.com/dementia_researcher/
https://www.facebook.com/Dementia.Researcher/
https://www.twitter.com/demrescommunity
https://www.linkedin.com/company/dementia-researcher
https://bsky.app/profile/dementiaresearcher.bsky.social

Download and Register with our Community App:
https://www.onelink.to/dementiaresearcher
We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research.
The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors.
Subscribe to our sister show 'Dementia Researcher The Blogs':
https://podfollow.com/dementia-researcher-blogs

In this episode of the Dementia Researcher Podcast Dr Anna Volkmer hosts a discussion exploring the complexities of wandering in dementia care.
Dr Bryony Waters-Harvey & Dr Emma Hock from The University of Sheffield and Conny McGowan from The Orders of St John Care Trust discuss their research and outcomes of the NIHR funded "FREEDEM study" - Reframing 'wandering' as a meaningful activity using realist synthesis and qualitative exploration
Takeaways
Wandering is often a meaningful activity for residents.
Individualised care plans are crucial for supporting residents.
Language matters in how we perceive wandering.
Positive risk-taking can enhance residents' quality of life.
Hydration and nutrition are important for wandering residents.
Research should focus on the positive aspects of wandering.
Care staff need training to support safe wandering.
Environmental factors significantly impact wandering behavior.
Residents should have access to outdoor spaces.
Future research should involve residents and their families

Access the toolkit and resources:
https://sites.google.com/sheffield.ac.uk/freedem/home
Strategies to support safe wandering in care homes for older adults – what works, for whom, and in which circumstances? A realist synthesis:
https://www.sciencedirect.com/science/article/pii/S0020748926000192
A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk.
If you prefer to watch rather than listen, you will find a video version of this podcast on YouTube, on our website, and in selected podcast platforms.
Follow us on social media:
https://www.instagram.com/dementia_researcher/
https://www.facebook.com/Dementia.Researcher/
https://www.twitter.com/demrescommunity
https://www.linkedin.com/company/dementia-researcher
https://bsky.app/profile/dementiaresearcher.bsky.social

Download and Register with our Community App:
https://www.onelink.to/dementiaresearcher
We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research.
The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors.
Subscribe to our sister show 'Dementia Researcher The Blogs':
https://podfollow.com/dementia-researcher-blogs

This episode of the Dementia Researcher Podcast continues our coverage from the AD PD Conference 2026 in Copenhagen, one of the largest international meetings focused on Alzheimer’s and Parkinson’s disease.
Hosted by Professor Louise Serpell, the conversation brings together Athina Grigoriou, Dr Lauren O’Neill, and Dr Sofie Let Frandsen, each sharing highlights from across the conference.
The discussion spans a wide range of topics, from the biological role of alpha synuclein and mitochondrial dysfunction, through to emerging therapeutic targets and the growing importance of biomarkers. There is a strong focus on how diseases are more complex and varied than once thought, with increasing attention on stratification, personalised medicine, and early detection.
Alongside the science, the episode also reflects on the importance of patient voices, collaboration across disciplines, and the value of sharing both positive and negative research findings.
This is Part Two of our AD PD 2026 reflections, offering a thoughtful look at where the field is heading next.
ADPD Conference Website - adpd.kenes.com/
Top Takeaways:
Alpha synuclein may have a normal physiological role, not just a pathological one
Mitochondrial dysfunction remains central in Parkinson’s mechanisms
Biomarkers are key for both early detection and patient stratification
Diseases like Parkinson’s and dementia are highly heterogeneous
Personalised medicine is becoming a realistic goal, not just an idea
New therapeutic targets beyond dopamine are emerging
Early stage and presymptomatic intervention is a major focus
Patient and carer perspectives remain underrepresented but essential
Collaboration and openness, including sharing negative results, are vital
More diverse populations are needed to validate biomarkers globally

A transcript of this show, links and show notes and profile on all our guests are available on our website at www.dementiaresearcher.nihr.ac.uk
Follow us on social media:
www.instagram.com/dementia_researcher/
www.facebook.com/Dementia.Researcher/
www.twitter.com/demrescommunity
www.linkedin.com/company/dementia-researcher
www.bsky.app/profile/dementiare…archer.bsky.social

Download and Register with our Community App:
www.onelink.to/dementiaresearcher

This episode of the Dementia Researcher Podcast comes from the AD PD Conference 2026 in Copenhagen, bringing together global researchers to share the latest in Alzheimer’s and Parkinson’s disease research.
Hosted by Professor David Cash, the episode features Grace Thompson, Dr Marieta Vassileva, and Dr Alice Carstairs, each offering their own highlights from across the conference.
Rather than trying to cover everything, the conversation focuses on standout talks and emerging themes. These include advances in biomarkers, growing interest in co pathology, the role of neuroinflammation, and how new tools like AI and multiomics are changing how we understand disease.
Across the discussion, the group reflects on what new findings might mean for diagnosis, treatment, and the future direction of dementia research. There is also a strong sense of optimism, with the field moving towards combination therapies and earlier intervention.
This is Part One of a two part series capturing reflections from the conference.
ADPD Conference Website - adpd.kenes.com/
Top Takeaways:
Biomarkers are now central across diagnosis, prediction, and trials
Co pathology is a major theme, with diseases rarely existing in isolation
Tau is emerging as a key driver of cognitive decline
Microglia and neuroinflammation offer new therapeutic targets
Multiomics is helping uncover detailed disease mechanisms
AI is becoming essential for handling complex datasets
Early career researchers are playing a visible role at major conferences
Synaptic loss is strongly linked to cognitive decline
Combination therapies are increasingly seen as the future
The field feels more optimistic than in previous years

A transcript of this show, links and show notes and profile on all our guests are available on our website at www.dementiaresearcher.nihr.ac.uk
Follow us on social media:
www.instagram.com/dementia_researcher/
www.facebook.com/Dementia.Researcher/
www.twitter.com/demrescommunity
www.linkedin.com/company/dementia-researcher
www.bsky.app/profile/dementiare…archer.bsky.social

Download and Register with our Community App:
www.onelink.to/dementiaresearcher

Primary progressive aphasia (PPA) is a group of language led dementias where communication difficulties appear before memory loss. Despite this, diagnosis can often take years and access to specialist support remains inconsistent.
In this episode of the Dementia Researcher Podcast, Dr Annalise Rahman Filipiak speaks with Professor Jason Warren, Dr Anna Volkmer and Dr Jacqueline Kindell about the role of speech and language therapy in diagnosing and supporting people living with PPA. The discussion explores why diagnosis is often delayed, how speech and language therapists contribute to multidisciplinary assessment and care pathways, and why early referral can make a meaningful difference for patients and families.
The conversation also looks at international differences in access to services, the importance of communication support across the course of the condition, and the growing global movement to improve awareness through Primary Progressive Aphasia Awareness Day.
PPA Awareness Day 2026 - speechtherapyppa.com/ppa-awareness-day
About the guests
Jason Warren - Professor of Neurology at University College London and the National Hospital for Neurology and Neurosurgery. His research focuses on dementia, language disorders and diagnostic markers for primary progressive aphasia.
Anna Volkmer - Associate Professor and Consultant Speech and Language Therapist at University College London. Her work focuses on communication interventions and support for people living with primary progressive aphasia and their families.
Jacqueline Kindell - Speech and Language Therapist and Lecturer at The University of Manchester with extensive clinical and research experience in dementia and communication disorders.
Key Takeaways
Primary progressive aphasia is a group of dementias where language difficulties appear before memory problems, which often makes diagnosis harder.
Diagnosis can take several years because many dementia assessment tools focus on memory rather than communication and language.
Speech and language therapists play an important role in diagnosing PPA by assessing language, communication and motor speech changes.
Speech and language therapy is currently the main treatment available to help people with PPA manage communication difficulties.
Early referral to speech and language therapy helps people and families adapt communication strategies and plan for future changes.
Access to specialist speech and language therapy services varies widely depending on where people live.
Communication support can improve quality of life and reduce wider pressures on health services by improving understanding between patients, families and clinicians.
Primary Progressive Aphasia Awareness Day aims to improve recognition of the condition and promote early referral to speech and language therapy.

A transcript of this show, links and show notes and profile on all our guests are available on our website at www.dementiaresearcher.nihr.ac.uk
Follow us on social media:
www.instagram.com/dementia_researcher/
www.facebook.com/Dementia.Researcher/
www.twitter.com/demrescommunity
www.linkedin.com/company/dementia-researcher
www.bsky.app/profile/dementiare…archer.bsky.social

Download and Register with our Community App:
www.onelink.to/dementiaresearcher